The Changing Landscape of Global Vaccine Development and Market Potential - - BioPharm International


The Changing Landscape of Global Vaccine Development and Market Potential

BioPharm International
Volume 20, Issue 10

13. Gao F, li Y, Decker JM, Peyerl FW, Bibollet-Ruche F, Rodenburg CM, et al. Codon Usage optimization of HIV type1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res. Hum Retroviuses. 2003;19:817–823.

14. Chugh P, Seth P. Induction of broad-based immune response against HIV-1 subtype C gag DNA vaccine in mice. Viral Immunol. 2004;17:423-435.

15. Scriba TJ, zur Megede J, Glashoff RH, Treurnicht FK, Barnett SW, van Rensburg EJ, Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine. 2005;23:1158-1169.

16. Ramakrishana L, Anand KK, Mohankumar KM, Ranga U. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice. J Gen Virol. 2004;85:409-413.

17. Van Harmelen JH, Shephard E, Tomas R, Hanke T, Williamson AL, Williamson C. Construction and characterization of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine. 2003;21:4380-4389.

18. Paris R, Bejrachandra S, karnasuta C, Chandanayingyong D, Kunachiwa W, Leetrakool N, et al, HLA class I serotype and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens. 2004;64:251-256.

19. HIVVaccine Network Current Vaccine Trials. http://

20. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus (HIV). 2006;24:4062-4081.

21. Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Chermak A, et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine. 2005;23:4292-4301.

22. Peters BS. The basis for HIV immunotherapeutic vaccines. Vaccine. 2002;20:688-705.

23. Garcia F, Lejeune M, Climent N, Gil C. Alcami J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis. 2005;191:1680-1685.

24. Wieman B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64:529-524.

25. Mazzaferro V, Coppa J, Carraba MG, Rivoltini L, et al. Vaccination with autologous tumor-derived heat-shocked protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003;9:3235-3245.

26. Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine. 2004;23:97-11.

27. Hamid O, Solomon JC, Scotland R, Garcia M, Sian S. et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res. 2007;13(1):215-222.

28. Berd D, Sato T, Maguire Jr HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous hapten-modified human melanoma vaccine. J Clin. Oncol. 2004;22:403-415.

29. Morton DL, Hsueh EC, Essner R. Foshag LJ, O'Day SJ, Bilehik A, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg. 2002;236:438-448.

blog comments powered by Disqus



J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines
Source: BioPharm International,
Click here